Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. [artículo]
Por: Ciruelos Gil, Eva María [Oncología Médica]
| Cortés-Funes Castro, Hernán [Oncología Médica] | Paz-Ares Rodríguez, Luis [Oncología Médica].
Colaborador(es): Servicio de Oncología Médica.
Tipo de material: 
LibroEditor: Investigational New Drugs, 2012Descripción: 30(2):729-40.Recursos en línea: Solicitar documento Resumen: This study assesses the efficacy, toxicity and pharmacokinetic profile of trabectedin with or without prophylactic dexamethasone co-treatment in patients with recurrent advanced soft tissue sarcoma (STS).
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
Disponible |
Formato Vancouver:
Paz-Ares L, López-Pousa A, Poveda A, Balañá C, Ciruelos E, Bellmunt J, et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs. 2012 Apr;30(2):729-40.
PMID: 20960029
Contiene 37 referencias
This study assesses the efficacy, toxicity and pharmacokinetic profile of trabectedin with or without prophylactic dexamethasone co-treatment in patients with recurrent advanced soft tissue sarcoma (STS).
No hay comentarios para este ejemplar.